Enzo Biochem Ready to Reveal EGS21 Data (NYSE:ENZ)
Source: http://feedproxy.google.com/~r/FavStocks/~3/Ga7oyJO4f_g/Posted on Tuesday, November 17th, 2009 | In Biotech, Investing Lessons, Stocks to Watch
Enzo Biochem Inc (NYSE:ENZ) has announced that their Vice President of Corporate Development, David Goldberg will speak about Company’s extensive oral immune regulation platform at the Windhover TA Partnerships 2009 Conference which will be held in Boston on Wednesday, November 18, 2009. The Company announced that Enzo Biochem’s EGS21, an orally administered beta glucosylceramide formulation, which is currently undergoing clinical study, has been named one of this year’s top 10 inflammatory and autoimmune projects to watch. The TA Partnership Conference is sponsored by Windhover Information Inc which is world’s leading publisher of science, technical and health information.
Enzo Biochem have already presented their EGS21 clinical studies data recently at the Liver Conference where they showed that the oral administration of EGS21 is safe and appears to be biologically active in patients with insulin resistance and NASH (non-alcoholic steatohepatitis). Mr. Goldberg stated that this is a welcome recognition by a leading industry information organization and they are pleased to see a positive response. He also mentioned that EGS21 is a formulation derived from Enzo’s pioneering therapeutic platform that utilizes oral immune regulation for immune mediated diseases. Further he said that Enzo Therapeutics subsidiary has always viewed oral immune regulation as an exciting and promising platform and therefore they have continued to pursue through studies involving treatment candidates for unmet medical needs.
Last 5 posts by Jay Garcilazo
- FDA Response to CPI-300’s NDA Anticipated Soon (NASDAQ:IGXT) - February 4th, 2010
- FDA Response to ODFS’s NDA Anticipated (NYSE:PRX) - February 4th, 2010
- FDA response on Autologel Sytem Expected Soon (AMEX:GTF) - February 4th, 2010
- FDA response on IL 13-PE expected on February 4, 2010 (NASDAQ:NEOL) - February 4th, 2010
- FDA Response Expected Expected Soon for Bovie (AMEX:BVX) - February 4th, 2010
 About Jay Garcilazo (http://favstocks.com)
I grew up in Boca Raton, Florida. After graduating high school I enrolled at Florida State University where I studied Journalism and Political Science. It was around this time that I got a job in the healthcare industry, a job that would give me a lot of experience as I worked and moved up over the next four and a half years. This along with working for a hedge fund manager for years, were the greatest learning experiences of my life so far. I have also been fortunate enough to have lived all over the country in, Austin, Texas, Queens, New York, Great Falls, Montana, Cleveland, Ohio, Chattanooga, Tennessee, Atlanta, Georgia, and all over the state of Florida. As well as living in many places I have traveled all over, been to all of the states except California (Had a layover at LAX once but I don’t think that counts), Oregon, and Hawaii. Traveled most of the Caribbean, I have also been to many destinations in Canada, and Mexico. I even did a stint through Europe. As well as traveling and living all over I have also worked in a great many industries. I have been employed in finance, healthcare, title, mortgage, travel, video game development, hospitality, and news industries. Besides working for an investment company I have also done quite a bit of investing on my own, and through trial and error, learning from mistakes, and watching the news very closely I have made some decent money for myself. |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.